MILFORD, Mass — June 1, 2026 — Waters Corporation (NYSE: WAT) today introduced the Waters Xevo™ MRT P10 Mass Spectrometer, a high resolution Quadrupole Time-of-Flight (QToF) System for high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories. The Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity compared to its predecessor, along with industry-leading speed and expanded acquisition modes to comprehensively support both targeted and untargeted analysis in a single benchtop platform. The system is designed to accelerate biomarker discovery and validation while supporting the identication of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies.
"With the Xevo MRT P10 MS, we are raising the standard for benchtop high-resolution mass spectrometry," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "By combining enhanced MS/MS sensitivity, the industry's fastest benchtop acquisition speeds, and advanced intelligent acquisition modes in LC-MS/MS – and layering in a new benchmark for th 1 MS imaging speed and throughput with our DESI XS – this platform empowers researchers to see more biology, accelerate discovery, and make condent decisions. The Xevo MRT P10 MS represents a powerful step forward for our customers working to advance multiomics research and life‑changing therapies."
As researchers pursue deeper analytical insights, they face a bottleneck: generating high quality MS/MS information at the speed required by modern workows. The Xevo MRT P10 MS is engineered to solve that problem. It offers up to 20× greater MS/MS sensitivity, helping scientists detect low-abundance compounds in complex samples. With acquisition speeds twice as fast as its predecessor, it is the fastest benchtop HRMS system currently available.
The new system supports rapid throughput, alongside exceptional resolution and mass accuracy, delivering the highest data quality and condence. When combined with the DESI XS ion source, rapid spatial analysis is unlocked down to the cellular level at up to 200 Hz, increasing throughput six-fold while preserving image quality.
"As a core research facility, we must be prepared to respond to challenging and often unexpected client requests, many of which relate to research into complex diseases," said Corey Broeckling, Director, Bioanalysis and Omics Center, Colorado State University. "We leverage the exceptional MS/MS sensitivity and fast acquisition rates of the Xevo MRT P10 MS for multiomics research. Its excellent resolution enables us to separate signals of similar mass at very high acquisition speeds, delivering deep, high-quality coverage while maintaining sub‑ppm mass accuracy. Combined with new acquisition modes, this provides the versatility and data condence we need across a wide range of omics applications."
The Xevo MRT P10 MS is perfectly positioned to support long-term growth across multiomics, including proteomics, lipidomics, and metabolomics, as well as biopharmaceutical analysis and drug discovery. The instrument unlocks new workows in high-throughput, deep proteome discovery by combining greater sensitivity with ultra-fast acquisition rates and advanced acquisition modes, allowing condent detection of low-abundance peptides and comprehensive protein identication with rapid separations at scale. In comparative lipid proling by LC-MS/MS, the Xevo MRT P10 MS enabled identication of up to 40 percent more lipids than the most competitive alternative system. These enhancements support more comprehensive biological interpretation in multiomics‑driven research and ultimately drive deeper levels of disease understanding.
The Xevo MRT P10 MS will be showcased at ASMS 2026 and is expected to be available globally beginning summer 2026. For more information or to request a demo, visit the product page.
